Overview
Biomerieux Polska operates in the field of in vitro diagnostics. bioMérieux products include the SPINCHIP hs-cTnI point-of-care platform for measuring troponin I and BIOFIRE panels for diagnosing respiratory infections and pneumonia.
Financials
Revenue history (in m)
Filing timeliness
Financial statements were filed on time, on average 85 days early.
- 202503/05/2026
- 202426/06/2025
- 202315/04/2024
- 202203/04/2023
- 202109/05/2022
- 202014/05/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Industry
Offer
- Diagnostic tests
- Immunoassay analyzers
- Microbiology tests
- Molecular tests
- Diagnostic reagents
Public procurement
1046 tenders recorded as contractor: 714 national ($30,137,942) and 332 EU ($251,774,008).
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Oct 28, 2026 | Supply of contrast injector consumables, reagents and kits for the Analytical Laboratory and Department of Pathomorphology, and reagents together with analyser lease for the Microbiology Laboratory – case No. Z/74/PN/26 | $10,211$10,211 | Regionalny Szpital Specjalistyczny Im. Dr. Władysława Biegańskiego | |
| Oct 27, 2026 | Lease of analyzers together with the supply of reagents, and supply of tests for the Diagnostic Laboratory of szpital Olmedica w Olecku Sp. z o. o. | $22,534$22,534 | Olmedica w Olecku sp. z o.o. | |
| Oct 26, 2026 | Wofitm/56/2026/pn – supply of laboratory tests | $46,515$46,515 | Wojskowy Ośrodek Farmacji i Techniki Medycznej - Celestynów |
Authorized Representatives
Manner of representation
When the management board is a one-person management board, the company is represented by a member of the management board acting jointly with a commercial proxy or by two joint commercial proxies.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Biomerieux S.A. | 360 | $97,244.73 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Biomerieux Ssc Europesp. z o.o. | 175,580.77 USD | 100% |
Bank accounts
Registered as a VAT taxpayer on 2003-12-31.
68 1600 1462 1846 4473 1000 0001
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 15,964PLN 15,964 |
Public aid
No public aid cases recorded in the last 10 years.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Roche Diagnostics Polskasp. z o.o. | $199,208,461.57 | roche.pl | ||
| SynektikS.A. | $120,322,164.42 | synektik.pl | ||
| Chiesi Polandsp. z o.o. | $87,762,158.97 | chiesi.pl | ||
| DiagnosisS.A. | $37,413,735.72 | diagnosis.pl | ||
| Sysmex Polskasp. z o.o. | $37,091,282.03 | sysmex.pl | ||
| Euroimmun Polskasp. z o.o. | $30,318,011.37 | euroimmun.pl | ||
| Shim-Pol A.M.Borzymowski E.Borzymowska-Reszka, A.Reszkasp. j. | $26,039,075.33 | shim-pol.pl | ||
| Synkmedsp. z o.o. | $20,634,200.47 | synkmed.pl | ||
| Midas Pharma Polskasp. z o.o. | $20,847,894.51 | midas-pharma.com | ||
| Werfen Polskasp. z o.o. | $14,536,720.51 | werfen.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-09-07 | PKD change (Removed: 70.22.Z, 71.20.B; Added: 70.20.Z, 71.20.C) | |
| 2016-07-13 | Switch to PKD 2007 (20 PKD 1997 codes → 10 PKD 2007 codes) | |
| 2013-06-19 | Address change (Żeromskiego 17, 01-882, Warszawa → Generała Józefa Zajączka 9, 01-518, Warszawa) | |
| 2004-05-05 | Address change (Żeromskiego 17, 01-822, Warszawa → Żeromskiego 17, 01-882, Warszawa) | |
| 2002-08-24 | Entered in the register |
FAQ
Last updated: 2026-10-02